Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9311 Rituximab and Hyaluronidase Rituxan Hycela 10mg Immunotherapy Monoclonal Antibody CD20 No 2017 Jan 1, 2019 In Use
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
J9023 Avelumab Bavencio 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2018 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct 1, 2017 In Use
NA Rucaparib Rubraca 250 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Ribociclib Kisqali 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
NA Ribociclib and letrozole Kisqali Femara Co-pack 200 mg/ 2.5 mg Chemotherapy, Hormonal Therapy Cyclin dependent kinase inhibitor/ aromatase inhibitor CDK 4/6 Yes 2017 In Use
C9024 (Daunorubicin AND Cytarabine) Liposome Vyxeos 1mg/2.27mg Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog No 2017 In Use
NA Rucaparib Rubraca 300 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
J9249 Melphalan (Apotex) Melphalan (Apotex) 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2017 Apr 17, 2024 In Use
C9492 Durvalumab Imfinzi 10 mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Oct 1, 2017 In Use
J9048 Bortezomib (Fresniuskab) Bortezomib (Fresniuskab) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2017 Dec 21, 2022 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
J9057 Copanlisib Aliqopa 1mg Chemotherapy Enzyme Inhibitor PI3K No 2017 In Use
NA Niraparib Zejula 100 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
J8612 Methotrexate (xatmep) Xatmep 2.5mg Chemotherapy Antimetabolite Folic Acid Analog Yes 2017 Jun 10, 2024 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
NA Brigatinib Alunbrig 30 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2017 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.